Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 10 » Issue 1

Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease

Authors Miravitlles M, Price D, Rabe KF, Schmidt H, Metzdorf N, Celli B

Received 29 July 2014

Accepted for publication 14 November 2014

Published 16 March 2015 Volume 2015:10(1) Pages 549—564

DOI https://doi.org/10.2147/COPD.S71913

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Dr Richard Russell

Marc Miravitlles,1 David Price,2 Klaus F Rabe,3,7 Hendrik Schmidt,4 Norbert Metzdorf,5 Bartolome Celli6

1Pneumology Department, Hospital Universitari Vall d’Hebron, Ciber de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK; 3Department of Medicine, Christian-Albrechts-Universität zu Kiel (CAU), Großhansdorf, Germany; 4Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany; 5TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH and Co KG, Ingelheim am Rhein, Germany; 6Pulmonary Division, Brigham and Women’s Hospital, Boston, MA, USA; 7LungenClinic Grosshansdorf, Großhansdorf, Germany

Background: There is an ongoing debate on whether patients with chronic obstructive pulmonary disease (COPD) seen in real-life clinical settings are represented in randomized controlled trials (RCTs) of COPD. It is thought that the stringent inclusion and exclusion criteria of RCTs may prevent the participation of patients with specific characteristics or risk factors.
Methods: We surveyed a database of patients recruited into 35 placebo-controlled tiotropium RCTs and also conducted a systematic literature review of large-scale observational studies conducted in patients with a documented diagnosis of COPD between 1990 and 2013. Patient demographics and comorbidities with a high prevalence in patients with COPD were compared between the two patient populations at baseline. Using the Medical Dictionary for Regulatory Activities (MedDRA; v 14.0), patient comorbidities in the pooled tiotropium RCTs were classified according to system organ class, pharmacovigilance (PV) endpoints, and Standardised MedDRA Queries to enable comparison with the observational studies.
Results: We identified 24,555 patients in the pooled tiotropium RCTs and 61,361 patients among the 13 observational studies that met our search criteria. The Global initiative for chronic Obstructive Lung Disease (GOLD) staging of patients in the RCTs differed from that in observational studies: the proportion of patients with GOLD stages I+II disease ranged from 40.0% to 51.5% in the RCTs but 24.5% to 44.1% in the observational studies; for GOLD stage III or IV disease these ranges were 7.2%–45.8% (RCTs) and 13.7–42.1% (observational studies). The comorbidities with the highest prevalence reported in the RCTs and observational studies were: hypertension (39.4%–40.0% vs 40.1%–60.6%), other ischemic heart disease (12.3%–14.2% vs 12.5%–41.0%), diabetes (10.3%–10.9% vs 4.0%–38.9%), depression (8.5%–9.5% vs 17.0%–20.6%), and cardiac arrhythmia (7.8%–11.4% vs 11.3%–15.8%).
Conclusion: The clinical profile of COPD patients treated in the tiotropium trial program appears to be largely in the range of clinical characteristics, including cardiovascular comorbidities, reported for “real-life patients.” The tiotropium RCTs tended to include patients with more severe disease than the observational studies.

Keywords: patient population, baseline characteristics, epidemiology, real-life patients, GOLD staging

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Palliative care and prognosis in COPD: a systematic review with a validation cohort

Almagro P, Yun S, Sangil A, Rodríguez-Carballeira M, Marine M, Landete P, Soler-Cataluña JJ, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1721-1729

Published Date: 9 June 2017

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1683-1694

Published Date: 8 June 2017

Bronchiectasis in COPD patients: more than a comorbidity?

Martinez-Garcia MA, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1401-1411

Published Date: 11 May 2017

Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics

Ramon MA, Esquinas C, Barrecheguren M, Pleguezuelos E, Molina J, Quintano JA, Roman-Rodríguez M, Naberan K, Llor C, Roncero C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1173-1181

Published Date: 13 April 2017

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:561-569

Published Date: 13 February 2017

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study

Barrecheguren M, Monteagudo M, Simonet P, Llor C, Rodriguez E, Ferrer J, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:999-1004

Published Date: 10 May 2016

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F, Ribera X

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:407-415

Published Date: 26 February 2016

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016

The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD

Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de los Monteros MJ, Esquinas C, Molina J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2571-2579

Published Date: 30 November 2015

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?

Barrecheguren M, Román-Rodríguez M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1745-1752

Published Date: 1 September 2015

What pulmonologists think about the asthma–COPD overlap syndrome

Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1321-1330

Published Date: 15 July 2015

Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease

Miravitlles M, Huerta A, Valle M, García-Sidro P, Forné C, Crespo C, López-Campos JL

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:367-377

Published Date: 16 February 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 5 December 2008

Readers of this article also read:

Epidemiology of chronic obstructive pulmonary disease: a population-based study in Krasnoyarsk region, Russia

Artyukhov IP, Arshukova IL, Dobretsova EA, Dugina TA, Shulmin AV, Demko IV

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1781-1786

Published Date: 2 September 2015

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?

Barrecheguren M, Román-Rodríguez M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1745-1752

Published Date: 1 September 2015

Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits

Chang CH, Tsao KC, Hu HC, Huang CC, Kao KC, Chen NH, Yang CT, Tsai YH, Hsieh MJ

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:767-774

Published Date: 13 April 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns

Price D, West D, Brusselle G, Gruffydd-Jones K, Jones R, Miravitlles M, Rossi A, Hutton C, Ashton VL, Stewart R, Bichel K

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:889-905

Published Date: 27 August 2014

Pathogenesis of hyperinflation in chronic obstructive pulmonary disease

Gagnon P, Guenette JA, Langer D, Laviolette L, Mainguy V, Maltais F, Ribeiro F, Saey D

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:187-201

Published Date: 15 February 2014